CurrentCignaPolicy N/A

Leqselvi (deuruxolitinib) prior authorization for alopecia areata

Defines prior authorization requirements, coverage criteria, and exclusions for Leqselvi tablets for treatment of alopecia areata for Cigna-administered health benefit plans and specifies prescribing and monitoring expectations for providers.

Policy Summary

PayerCigna

PolicyLeqselvi (deuruxolitinib) prior authorization for alopecia areata

Policy CodePolicy N/A

Change TypeCoverage exclusions added/clarified

Effective DateN/A

Next Review DateAug 20, 2025

Key ActionObtain prior authorization; initial approvals are for 6 months and continuation approvals for 1 year when criteria are met.

SourceLink

POLICY UPDATE CHANGES

Conditions Not Covered: Concurrent use with a Biologic or with a Targeted Synthetic Oral Small Molecule Drug was added.

Concomitant use with an oral or topical JAK inhibitor was changed to list 'Concomitant Use with a Topical JAK Inhibitor.'

≥18min patient age

≥6 momin episode duration

≥50%min scalp hair loss

6 moinitial approval

1 yrcontinuation approval

Coverage Criteria for Leqselvi (deuruxolitinib)

Alopecia Areata Coverage Criteria

Covered when ONE of the following is met:

A or B: A) Initial Therapy OR B) Currently Receiving Leqselvi

A) Initial Therapy

A.i Age: Patient is ≥ 18 years of age>=18 years
A.ii CYP2C9 status: Patient is not a cytochrome P450 2C9 poor metabolizer as assessed by an approved test

Policy Summary

PayerCigna

PolicyLeqselvi (deuruxolitinib) prior authorization for alopecia areata

Policy CodePolicy N/A

Change TypeCoverage exclusions added/clarified

Effective DateN/A

Next Review DateAug 20, 2025

Key ActionObtain prior authorization; initial approvals are for 6 months and continuation approvals for 1 year when criteria are met.

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

B) Currently Receiving Leqselvi

B.i Age: Patient is ≥ 18 years of age>=18 years
B.ii Prior exposure: Patient has been established on Leqselvi for at least 6 months>=6 months on therapy
Patients with <6 months or restarting are reviewed under Initial Therapy
B.iii Clinical response: Patient experienced a beneficial clinical response, defined as improvement from baseline in extent and density of scalp hair
B.iv Ongoing need: According to the prescriber, the patient continues to require systemic therapy for treatment of alopecia areata

Leqselvi should not be used concurrently with certain other systemic or topical immunomodulatory therapies. Specifically, concurrent use with a biologic or with a targeted synthetic oral small molecule drug is not recommended due to a potentially higher rate of adverse events and lack of controlled clinical data supporting additive efficacy. The policy also prohibits concurrent use with a topical Janus kinase inhibitor (JAKi) (examples include Opzelura [ruxolitinib cream] and Anzupgo [delgocitinib cream]). Additionally, concurrent use with biologic immunomodulators (examples: Adbry, Dupixent, Fasenra, Nucala, Tezspire, Xolair, etc.) and concurrent use with other potent immunosuppressants (e.g., cyclosporine, azathioprine) is not recommended because of the increased risk of additive immunosuppression.

Provider Requirements, Documentation, and Denial Triggers

Prior Authorization

Prior Authorization Required

Prior Authorization is required for Leqselvi. Initial approvals are authorized for 6 months; continuation (maintenance) approvals are authorized for 1 year. Approvals measured in months use 30-day months. Because of specialized evaluation and monitoring needs, initial approval requires the medication to be prescribed by or in consultation with a physician who specializes in the condition being treated (dermatologist for alopecia areata).

Initial approval duration: 6 months (1 month = 30 days)
Continuation approval duration: 1 year
Initial prescription must be by or in consultation with a specialist (dermatologist for alopecia areata)

Step Therapy

Prior Therapy Requirement

Prior therapy requirement: for initial therapy the patient must have tried at least ONE of the following options before Leqselvi is approved — a conventional systemic therapy OR a high- or super-high potency topical corticosteroid. Examples of conventional systemic therapies include corticosteroids, methotrexate, and cyclosporine. An exception to the requirement for a trial of one conventional systemic agent can be made if the patient has already tried Litfulo (ritlecitinib) or Olumiant (baricitinib).

Required trial of ≥1: conventional systemic therapy (e.g., corticosteroids, methotrexate, cyclosporine) OR high- or super-high potency topical corticosteroid
Exception: prior use of Litfulo (ritlecitinib) or Olumiant (baricitinib) may substitute for a conventional systemic trial

Documentation Required

Required Documentation Elements

Required documentation must be provided to support medical necessity and the authorization request. Documentation should include specialist prescription/consultation and evidence of prior therapies and clinical status.

Specialist involvement: prescription by or documentation of consultation with a dermatologist (for alopecia areata)
Patient age and metabolizer status: documentation that patient is ≥ 18 years and is not a CYP2C9 poor metabolizer (if applicable testing performed)
Clinical history: duration of current alopecia areata episode (≥ 6 months) and extent of scalp hair loss (≥ 50%)
Prior therapy evidence: records showing trial(s) of conventional systemic therapy or high-/super-high potency topical corticosteroid, or prior use of Litfulo/Olumiant if claiming exception
For continuation requests: documentation of at least 6 months on Leqselvi and evidence of beneficial clinical response (improvement from baseline in extent and density of scalp hair loss)

Denial Risk

Denial Triggers

Denial triggers include lack of a covered diagnosis or procedure code, concurrent disallowed therapies, missing required documentation, or failure to meet clinical or prior-therapy criteria.

Missing or non-covered diagnosis/procedure codes will result in denial
Concurrent use with biologics, targeted synthetic oral small molecule drugs for inflammatory conditions, topical JAK inhibitors, biologic immunomodulators, or other potent immunosuppressants (e.g., cyclosporine, azathioprine) is not allowed and will trigger denial
Requests for indications or combinations considered not medically necessary per policy will be denied
Incomplete documentation of specialist consultation/prescription, age/CYP2C9 status, duration/extent of disease, prior therapy trials, or clinical response for continuation will result in denial

Background on Leqselvi and Indication

Leqselvi (deuruxolitinib) is a Janus kinase (JAK) inhibitor indicated for the treatment of severe alopecia areata in adults. It inhibits multiple JAK enzymes and, as noted in clinical guidance, JAK inhibitors are recognized among systemic, steroid‑sparing options for extensive hair loss while topical or systemic corticosteroids remain first‑line. For this policy, coverage is limited to the FDA‑approved alopecia areata indication and excludes use in combination with the concurrent agents listed due to safety and efficacy concerns.

OpenPayer

Leqselvi (deuruxolitinib) prior authorization for alopecia areata

Coverage Criteria for Leqselvi (deuruxolitinib)

Key Clinical Thresholds and Coding-relevant Details

Provider Requirements, Documentation, and Denial Triggers

Background on Leqselvi and Indication

Definitions and Subtypes